Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector

Abstract
Learning Objectives: After completing this course, the reader will be able to: Select appropriate multidisciplinary treatment regimens and cytoprotection for clinical trials for patients with head and neck cancer.Identify radiation toxicity for the head and neck, lung, and pelvic irradiated areas.Describe the cytoprotective effect of amifostine against radiation toxicity. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com